Observational study of Everolimus in Pancreatic Neuroendocrine Tumors

• Research type

  Research Study

• Full title

  A Phase IV Observational study to assess Quality of Life in patients with Pancreatic Neuroendocrine Tumors receiving treatment with oral 10 mg Everolimus (Afinitor®) o.d.: The OBLIQUE Study (CRAD001PGB12)

• IRAS ID

  122173

• Contact name

  John Ramage

• Contact email

  John.Ramage@hhft.nhs.uk

• Sponsor organisation

  Novartis Pharmaceuticals UK Ltd.

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  13/SC/0121

• Date of REC Opinion

  26 Mar 2013

• REC opinion

  Favourable Opinion